Showing results (11-20 of 43) with videos related to

Sort By:
Pageof 5
European Journal of Cancer (Oxford, England : 1990)|October 14, 2019
Preclinical models of breast cancer: Two-way shuttles for immune checkpoint inhibitors from and to patient bedsideAmal Kamal Abdel-Aziz, Mona Kamal Saadeldin, Paolo D'Amico, et al.
Cancer Research|December 3, 2020
Cyclophosphamide and Vinorelbine Activate Stem-Like CD8+ T Cells and Improve Anti-PD-1 Efficacy in Triple-Negative Breast CancerPaolo Falvo, Stefania Orecchioni, Roman Hillje, et al.
Cell Death Discovery|March 9, 2022
A single-cell transcriptomic landscape of innate and adaptive intratumoral immunity in triple negative breast cancer during chemo- and immunotherapiesLaura Carpen, Paolo Falvo, Stefania Orecchioni, et al.
Scientific Reports|August 13, 2015
Lung Cancer Onset in Wild Type Mice Following Bone Marrow Reconstitution with kras(v12) CellsElena Belloni, Ines Martin Padura, Elvira Gerbino, et al.
Cell Death and Differentiation|January 27, 2025
Age-dependent differences in breast tumor microenvironment: challenges and opportunities for efficacy studies in preclinical modelsPaolo Falvo, Stephan Gruener, Stefania Orecchioni, et al.
International Journal of Cancer|September 9, 2014
The biguanides metformin and phenformin inhibit angiogenesis, local and metastatic growth of breast cancer by targeting both neoplastic and microenvironment cellsStefania Orecchioni, Francesca Reggiani, Giovanna Talarico, et al.
Human Pathology|May 25, 2019
Recurrent PDL1 expression and PDL1 (CD274) copy number alterations in breast implant-associated anaplastic large cell lymphomasValentina Tabanelli, Chiara Corsini, Stefano Fiori, et al.
Carcinogenesis|January 15, 2014
Paradoxic effects of metformin on endothelial cells and angiogenesisKatiuscia Dallaglio, Antonino Bruno, Anna R Cantelmo, et al.
Scientific Reports|January 6, 2016
Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cellsGiovanna Talarico, Stefania Orecchioni, Katiuscia Dallaglio, et al.
Scientific Reports|December 18, 2015
The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemiaMatteo Allegretti, Maria Rosaria Ricciardi, Roberto Licchetta, et al.
Pageof 5